Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe

- Age 18 years or older at the time of carfilzomib initiation - At least one prior line of MM treatment has been received - Carfilzomib treatment has been initiated per routine practice and is currently ongoing - At least one administration of carfilzomib in a combination regimen (ie, not monotherapy) has been received - Provided written informed consent prior to abstraction of any data, in countries where written informed consent is required. - Subjects who previously completed treatment with carfilzomib in a clinical trial, a compassionate use program or through routine practice, are eligible to take part in the study. - Subjects who receive radiotherapy concurrently with carfilzomib treatment are also eligible to take part in the study. - Subjects who initiate carfilzomib treatment on a combination regimen, subsequently discontinue all concomitant medications but remain on carfilzomib monotherapy in later cycles, remain eligible for participation in the study. - Subjects who are also enrolled in other observational studies in which standard of care is not altered are eligible to take part in the study,

- Subjects who are enrolled in a carfilzomib clinical trial will not be eligible to additionally take part in this observational study. - Subjects who are receiving carfilzomib treatment within a compassionate use program will not be eligible to take part in this observational study. If a subject who has enrolled into this observational study, also enrolls in a clinical trial in which MM treatment and/or disease management is protocol-specified, the subject becomes ineligible and the subject’s data will be censored from the time the subject enrolled the clinical trial.